Published in Br J Cancer on May 17, 2004
PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro. Breast Cancer Res (2009) 5.20
Tailoring to RB: tumour suppressor status and therapeutic response. Nat Rev Cancer (2008) 3.16
Progesterone signalling in breast cancer: a neglected hormone coming into the limelight. Nat Rev Cancer (2013) 2.60
Pathways to tamoxifen resistance. Cancer Lett (2007) 2.12
Anti-estrogen resistance in breast cancer is induced by the tumor microenvironment and can be overcome by inhibiting mitochondrial function in epithelial cancer cells. Cancer Biol Ther (2011) 1.43
Androgen receptor overexpression induces tamoxifen resistance in human breast cancer cells. Breast Cancer Res Treat (2009) 1.35
Histone deacetylase inhibitor, trichostatin A induces ubiquitin-dependent cyclin D1 degradation in MCF-7 breast cancer cells. Mol Cancer (2006) 1.18
Transcription Factor STAT3 as a Novel Molecular Target for Cancer Prevention. Cancers (Basel) (2014) 1.17
Gene products of chromosome 11q and their association with CCND1 gene amplification and tamoxifen resistance in premenopausal breast cancer. Breast Cancer Res (2008) 1.15
Inhibition of cyclin D1 expression by androgen receptor in breast cancer cells--identification of a novel androgen response element. Nucleic Acids Res (2010) 1.06
SLUG-induced elevation of D1 cyclin in breast cancer cells through the inhibition of its ubiquitination. J Biol Chem (2010) 1.05
Palbociclib: an evidence-based review of its potential in the treatment of breast cancer. Breast Cancer (Dove Med Press) (2014) 1.05
Cyclin D1 expression in colorectal cancer is a favorable prognostic factor in men but not in women in a prospective, population-based cohort study. Biol Sex Differ (2011) 1.04
Effects of cyclin D1 gene amplification and protein expression on time to recurrence in postmenopausal breast cancer patients treated with anastrozole or tamoxifen: a TransATAC study. Breast Cancer Res (2012) 1.03
Analysis of cyclins A, B1, D1 and E in breast cancer in relation to tumour grade and other prognostic factors. BMC Res Notes (2009) 1.03
Cell cycle and anti-estrogen effects synergize to regulate cell proliferation and ER target gene expression. PLoS One (2010) 0.99
Activity and intracellular location of estrogen receptors alpha and beta in human bronchial epithelial cells. Mol Cell Endocrinol (2009) 0.96
Reliability of cyclin A assessment on tissue microarrays in breast cancer compared to conventional histological slides. Br J Cancer (2006) 0.94
CyclinD1 protein plays different roles in modulating chemoresponses in MCF7 and MDA-MB231 cells. J Carcinog (2012) 0.89
Zinc protoporphyrin regulates cyclin D1 expression independent of heme oxygenase inhibition. J Biol Chem (2009) 0.86
Progesterone receptor-cyclin D1 complexes induce cell cycle-dependent transcriptional programs in breast cancer cells. Mol Endocrinol (2014) 0.84
Cyclin D1 and Rb protein expression and their correlation with prognosis in patients with colon cancer. World J Surg Oncol (2006) 0.82
Iodine alters gene expression in the MCF7 breast cancer cell line: evidence for an anti-estrogen effect of iodine. Int J Med Sci (2008) 0.82
Potent inhibition of rhabdoid tumor cells by combination of flavopiridol and 4OH-tamoxifen. BMC Cancer (2010) 0.82
Challenges in the management of advanced, ER-positive, HER2-negative breast cancer. Nat Rev Clin Oncol (2015) 0.81
Overcoming Endocrine Resistance in Hormone-Receptor Positive Advanced Breast Cancer-The Emerging Role of CDK4/6 Inhibitors. Int J Cancer Clin Res (2015) 0.81
Regulation of hormonal therapy resistance by cell cycle machinery. Gene Ther Mol Biol (2008) 0.79
Longer survival in patients with breast cancer with cyclin d1 over-expression after tumor recurrence: longer, but occupied with disease. J Breast Cancer (2014) 0.79
RSF1 and not cyclin D1 gene amplification may predict lack of benefit from adjuvant tamoxifen in high-risk pre-menopausal women in the MA.12 randomized clinical trial. PLoS One (2013) 0.78
The role of oncogenes in gastrointestinal cancer. Gastrointest Cancer Res (2010) 0.78
Association of Over-Expressed Estrogen Receptor Alpha with Development of Tamoxifen Resistant Hyperplasia and Adenocarcinomas in Genetically Engineered Mice. Anat Physiol (2012) 0.77
Short-term anastrozole therapy reduces Ki-67 and progesterone receptor expression in invasive breast cancer: a prospective, placebo-controlled, double-blind trial. J Cancer Res Clin Oncol (2010) 0.76
Progress with palbociclib in breast cancer: latest evidence and clinical considerations. Ther Adv Med Oncol (2016) 0.75
Cyclin D1 overexpression correlates with poor tumor differentiation and prognosis in gastric cancer. Oncol Lett (2017) 0.75
High expression of cyclin D1 is associated to high proliferation rate and increased risk of mortality in women with ER-positive but not in ER-negative breast cancers. Breast Cancer Res Treat (2017) 0.75
Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A (2001) 71.82
Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet (1998) 22.64
Cyclin D1 provides a link between development and oncogenesis in the retina and breast. Cell (1995) 6.08
Mammary hyperplasia and carcinoma in MMTV-cyclin D1 transgenic mice. Nature (1994) 5.34
Endocrine-responsive breast cancer and strategies for combating resistance. Nat Rev Cancer (2002) 4.57
CDK-independent activation of estrogen receptor by cyclin D1. Cell (1997) 3.85
Expression and amplification of cyclin genes in human breast cancer. Oncogene (1993) 3.79
Cyclin D1 stimulation of estrogen receptor transcriptional activity independent of cdk4. Mol Cell Biol (1997) 2.40
Cyclin D1 and prognosis in human breast cancer. Int J Cancer (1996) 2.11
Ligand-independent recruitment of steroid receptor coactivators to estrogen receptor by cyclin D1. Genes Dev (1998) 1.97
P/CAF associates with cyclin D1 and potentiates its activation of the estrogen receptor. Proc Natl Acad Sci U S A (1999) 1.68
Overexpression of cyclin D1 messenger RNA predicts for poor prognosis in estrogen receptor-positive breast cancer. Clin Cancer Res (1999) 1.65
Cyclin D1 expression in invasive breast cancer. Correlations and prognostic value. Am J Pathol (1997) 1.54
A clinicopathological study on overexpression of cyclin D1 and of p53 in a series of 248 patients with operable breast cancer. Br J Cancer (1996) 1.37
Oestrogen receptors in breast tumours: associations with age, menopausal status and epidemiological and clinical features in 735 patients. Br J Cancer (1980) 1.24
Regulation of the functional interaction between cyclin D1 and the estrogen receptor. Mol Cell Biol (2000) 1.22
Constitutive overexpression of cyclin D1 but not cyclin E confers acute resistance to antiestrogens in T-47D breast cancer cells. Cancer Res (2002) 1.21
Prognostic value of combined analysis of cyclin D1 and estrogen receptor status in breast cancer patients. Pathol Int (2003) 1.20
Prognostic value of CCND1 gene status in sporadic breast tumours, as determined by real-time quantitative PCR assays. Br J Cancer (2002) 1.06
Constitutive overexpression of cyclin D1 does not prevent inhibition of hormone-responsive human breast cancer cell growth by antiestrogens. Cancer Res (1998) 1.00
Involvement of G1/S cyclins in estrogen-independent proliferation of estrogen receptor-positive breast cancer cells. Oncogene (2002) 0.98
Expression and amplification of cyclin D1 in primary breast carcinomas: relationship with histopathological types and clinico-pathological parameters. Oncol Rep (2002) 0.98
Cyclin D1 expression and patient outcome after tamoxifen therapy in estrogen receptor positive metastatic breast cancer. Oncol Rep (2002) 0.97
Short recurrence-free survival associated with high oestrogen receptor levels in the natural history of postmenopausal, primary breast cancer. Eur J Cancer (1993) 0.89
Cyclin D1 in breast premalignancy and early breast cancer: implications for prevention and treatment. Cancer Lett (2001) 0.83
Intense metabolic control by means of insulin in patients with diabetes mellitus and acute myocardial infarction (DIGAMI 2): effects on mortality and morbidity. Eur Heart J (2005) 5.40
Effect on mortality of metoprolol in acute myocardial infarction. A double-blind randomised trial. Lancet (1981) 4.75
Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI study): effects on mortality at 1 year. J Am Coll Cardiol (1995) 4.50
Effects of the early administration of enalapril on mortality in patients with acute myocardial infarction. Results of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II) N Engl J Med (1992) 3.87
[Acute coronary syndromes. Simplified routines with early exercise test performed at the intensive coronary care units]. Lakartidningen (1993) 3.19
Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group. Circulation (1999) 3.06
Newly detected abnormal glucose tolerance: an important predictor of long-term outcome after myocardial infarction. Eur Heart J (2004) 2.80
A comparison of the acute and long-term hemodynamic effects of ventricular inhibited and atrial synchronous ventricular inhibited pacing. Circulation (1982) 2.22
Lipoprotein(a) as a determinant of coronary heart disease in young women. Circulation (1997) 2.13
Histopathological risk factors for ipsilateral breast events after breast conserving treatment for ductal carcinoma in situ of the breast--results from the Swedish randomised trial. Eur J Cancer (2006) 2.09
The role of AIB1 and PAX2 in primary breast cancer: validation of AIB1 as a negative prognostic factor. Ann Oncol (2012) 2.02
Completion axillary dissection can safely be omitted in screen detected breast cancer patients with micrometastases. A decade's experience from a single institution. Eur J Surg Oncol (2013) 1.99
Effects of insulin treatment on cause-specific one-year mortality and morbidity in diabetic patients with acute myocardial infarction. DIGAMI Study Group. Diabetes Insulin-Glucose in Acute Myocardial Infarction. Eur Heart J (1996) 1.83
HER2 expression in breast cancer primary tumours and corresponding metastases. Original data and literature review. Br J Cancer (2004) 1.79
Expression of vascular endothelial growth factor protein in human renal cell carcinoma. BJU Int (2004) 1.79
Oestrogen receptors alpha and beta show different associations to clinicopathological parameters and their co-expression might predict a better response to endocrine treatment in breast cancer. J Clin Pathol (2008) 1.79
Pacing in hypertrophic obstructive cardiomyopathy. A randomized crossover study. PIC Study Group. Eur Heart J (1997) 1.76
Admission plasma glucose. Independent risk factor for long-term prognosis after myocardial infarction even in nondiabetic patients. Diabetes Care (1999) 1.72
Cost-effectiveness of intense insulin treatment after acute myocardial infarction in patients with diabetes mellitus; results from the DIGAMI study. Eur Heart J (2000) 1.60
Adjuvant chemotherapy plus tamoxifen compared with tamoxifen alone for postmenopausal breast cancer: meta-analysis of quality-adjusted survival. Lancet (1996) 1.58
Aetiological aspects on primary liver cancer with special regard to alcohol, organic solvents and acute intermittent porphyria--an epidemiological investigation. Br J Cancer (1984) 1.56
Difference in mortality between patients treated with captopril or enalapril in the Xamoterol in Severe Heart Failure Study. Am J Cardiol (1991) 1.52
Accumulation of T lymphocytes and expression of interleukin-2 receptors in nonrheumatic stenotic aortic valves. J Am Coll Cardiol (1994) 1.46
Control of blood pressure and risk of first acute myocardial infarction: Skaraborg hypertension project. BMJ (1994) 1.46
Social relations and extent and severity of coronary artery disease. The Stockholm Female Coronary Risk Study. Eur Heart J (1998) 1.45
Continuous ambulatory haemodynamic monitoring with an implantable system. The feasibility of a new technique. Eur Heart J (1998) 1.44
Beta cell dysfunction in patients with acute myocardial infarction but without previously known type 2 diabetes: a report from the GAMI study. Diabetologia (2005) 1.44
Continuous haemodynamic monitoring during withdrawal of diuretics in patients with congestive heart failure. Eur Heart J (2002) 1.42
Phenformin and pulmonary hypertension. Br Heart J (1973) 1.40
Quantitative analysis of the expression and regulation of an activation-regulated phosphoprotein (oncoprotein 18) in normal and neoplastic cells. Leukemia (1993) 1.40
A new apparatus for detection of impending pacemaker failure in patients treated with implanted pacemakers. Cardiovasc Res (1970) 1.39
Preparation and properties of the major copper-binding component in human fetal liver. Its identification as metallothionein. J Biol Chem (1978) 1.37
Monitoring of mixed venous oxygen saturation and pressure from biosensors in the right ventricle. A 24 hour study in patients with heart failure. Eur Heart J (1995) 1.37
Reinvestigation of some physicochemical and chemical properties of human ceruloplasmin (ferroxidase). Biochemistry (1976) 1.36
A rapid and specific method for isolation of thiol-containing peptides from large proteins by thiol-disulfide exchange on a solid support. Proc Natl Acad Sci U S A (1975) 1.33
Human colorectal cancers with an intact p16/cyclin D1/pRb pathway have up-regulated p16 expression and decreased proliferation in small invasive tumor clusters. Am J Pathol (2000) 1.33
Deregulation of cyclin E and D1 in breast cancer is associated with inactivation of the retinoblastoma protein. Oncogene (1997) 1.33
Joint efforts across national boundaries between professional organizations in cardiovascular medicine: one way into the future. Eur Heart J (2000) 1.31
Re-used pacemakers--as safe as new? A retrospective case-control study. Eur Heart J (1998) 1.31
Myocardial infarction in patients with diabetes mellitus. Eur Heart J (1988) 1.30
Hypoxia, Snail and incomplete epithelial-mesenchymal transition in breast cancer. Br J Cancer (2009) 1.29
Two-year results of a controlled study of residential rehabilitation for patients treated with percutaneous transluminal coronary angioplasty. A randomized study of a multifactorial programme. Eur Heart J (1999) 1.28
Colon cancer, physical activity, and occupational exposures. A case-control study. Cancer (1989) 1.28
Haemorrhagic and thromboembolic complications in patients with atrial fibrillation on anticoagulant prophylaxis. J Intern Med (1989) 1.26
Mode of death in heart failure: findings from the ATLAS trial. Heart (2003) 1.24
Expression of oncoprotein 18 in human leukemias and lymphomas. Leukemia (1993) 1.23
Improved physical fitness and quality of life following training of elderly patients after acute coronary events. A 1 year follow-up randomized controlled study. Eur Heart J (1999) 1.23
Hypoxia and breast cancer: prognostic and therapeutic implications. Cell Mol Life Sci (2007) 1.21
Quality-of-life in patients treated with atrioventricular synchronous pacing compared to rate modulated ventricular pacing: a long-term, double-blind, crossover study. Pacing Clin Electrophysiol (1992) 1.21
A cell-cycle nuclear autoantigen containing WD-40 motifs expressed mainly in S and G2 phase cells. Biochem Biophys Res Commun (1995) 1.20
Cyclin E overexpression, a negative prognostic factor in breast cancer with strong correlation to oestrogen receptor status. Br J Cancer (1996) 1.19
Aortic valve replacement in octogenarians with aortic stenosis: a case-control study. J Am Coll Cardiol (1992) 1.18
Physiological versus single-rate ventricular pacing: a double-blind cross-over study. Pacing Clin Electrophysiol (1985) 1.16
Autoantibodies to a novel cell cycle-regulated protein that accumulates in the nuclear matrix during S phase and is localized in the kinetochores and spindle midzone during mitosis. J Cell Sci (1993) 1.15
Joint efforts across national boundaries between professional organizations in cardiovascular medicine: one way into the future. J Am Coll Cardiol (2000) 1.15
Chronic atrial fibrillation. Long-term results of direct current conversion. Acta Med Scand (1988) 1.15
Single-chain structure of human ceruloplasmin. Eur J Biochem (1972) 1.14
Comparison of physical work capacity and systolic time intervals with ventricular inhibited and atrial synchronous ventricular inhibited pacing. Br Heart J (1981) 1.14
The effect of ventricular activation sequence on cardiac performance during pacing. Pacing Clin Electrophysiol (1996) 1.14
Augmented metabolic control improves myocardial diastolic function and perfusion in patients with non-insulin dependent diabetes. Heart (2004) 1.12
Management of atrial fibrillation: discrepancy between guideline recommendations and actual practice exposes patients to risk for complications. Eur Heart J (2001) 1.12
Molecular weight of beef heart aconitase and stoichiometry of the components of its iron-sulfur cluster. J Biol Chem (1984) 1.12
Isolation and properties of a staphylococcal protease, preferentially cleaving glutamoyl-peptide bonds. Eur J Biochem (1974) 1.12
Epidemiological study of socioeconomic factors and clinical findings in Hodgkin's disease, and reanalysis of previous data regarding chemical exposure. Br J Cancer (1983) 1.10
Tocainide kinetics after intravenous and oral administration in healthy subjects and in patients with acute myocardial infarction. Clin Pharmacol Ther (1980) 1.10
Prognostic significance of p27(Kip1) expression in colorectal cancer: a clinico-pathological characterization. J Pathol (1999) 1.10
Causes of more frequent deletions than insertions in mutations and protein evolution. Nature (1981) 1.10
G1-S transition defects occur in most breast cancers and predict outcome. Breast Cancer Res Treat (1999) 1.10
Diabetes mellitus and congestive heart failure. Further knowledge needed. Eur Heart J (1999) 1.09
Phosphorylation of the oestrogen receptor alpha at serine 305 and prediction of tamoxifen resistance in breast cancer. J Pathol (2009) 1.09
Long term experience of felodipine in combination with beta-blockade and diuretics in refractory hypertension. Drugs (1985) 1.08
Expression of cyclin E and the cyclin-dependent kinase inhibitor p27 in malignant lymphomas-prognostic implications. Blood (1998) 1.08
Pathology parameters and adjuvant tamoxifen response in a randomised premenopausal breast cancer trial. J Clin Pathol (2005) 1.07
A double-blind trial of metoprolol in acute myocardial infarction. Effects on ventricular tachyarrhythmias. N Engl J Med (1983) 1.06
Placebo effect of pacemaker implantation in obstructive hypertrophic cardiomyopathy. PIC Study Group. Pacing In Cardiomyopathy. Am J Cardiol (1999) 1.06
Analysis of the epitopes of proliferating cell nuclear antigen recognized by monoclonal antibodies. Lab Invest (1993) 1.05
Sustained effect of hydralazine in long term treatment of CHF. Acta Med Scand Suppl (1981) 1.05
Results of atrioventricular synchronous pacing with optimized delay in patients with severe congestive heart failure. Am J Cardiol (1995) 1.04
Expression of cyclin D1 and retinoblastoma protein in colorectal cancer. Eur J Cancer (1998) 1.03
Metoprolol and atenolol administered once daily in primary hypertension. A clinical comparison of the efficacy of two selective beta-adrenoceptor blocking agents. Acta Med Scand (1981) 1.01
The amino-acid sequences of three tryptic glycopeptides from human ceruloplasmin. Eur J Biochem (1974) 1.01
Effect of lignocaine on heart rate in patients with sinus bradycardia associated with proven or suspected acute myocardial infarction. Cardiovasc Res (1972) 1.01
Clinical and electrophysiological characteristics of a transvenous atrial lead. Br Heart J (1979) 1.00
Expression of cyclin D1, D3, E, and p27 in human renal cell carcinoma analysed by tissue microarray. Br J Cancer (2003) 1.00
Tissue microarray analyses of G1/S-regulatory proteins in ductal carcinoma in situ of the breast indicate that low cyclin D1 is associated with local recurrence. Br J Cancer (2003) 1.00
Reduction of hospital days by biventricular pacing. Eur J Heart Fail (2000) 0.99
Predictive value of p53, mdm-2, p21, and mib-1 for chemotherapy response in advanced breast cancer. Clin Cancer Res (2000) 0.99
Mortality prediction in diabetic patients with myocardial infarction: experiences from the DIGAMI study. Cardiovasc Res (1997) 0.98
The Göteborg metoprolol trial. Effects on mortality and morbidity in acute myocardial infarction. Circulation (1983) 0.98
Methylation of the p16(Ink4a) tumor suppressor gene 5'-CpG island in breast cancer. Cancer Lett (2001) 0.97
A model of the three-dimensional structure of snake venom neurotoxins based on chemical evidence. Int J Pept Protein Res (1973) 0.97
Determination of the epitope of an inhibitory antibody to proliferating cell nuclear antigen. Exp Cell Res (1996) 0.97